So-Young International Inc. (SY) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary shows strong financial metrics, particularly in revenue growth expectations, and a strategic focus on expansion and vertical integration. While there are net losses, management provides optimistic guidance with plans for significant expansion and market share capture. The Q&A highlights management's confidence in market potential and effective cost strategies, with clear responses to analysts' questions. The partnership with SkinCeuticals and focus on proprietary product development further enhance the positive outlook. Despite the lack of market cap data, the overall sentiment suggests a positive stock price movement.
Key Financial Performance
Total Revenue RMB 378.7 million, down 7% year-over-year, primarily due to a decrease in the number of medical service providers subscribing to information services on our platform.
Aesthetic Treatment Service Revenues RMB 144.4 million, soaring 426.1% year-over-year, exceeding the high end of our guidance, primarily due to the business expansion of our branded aesthetic centers.
Information and Reservation Services Revenues RMB 135.2 million, down 35.6% year-over-year, primarily due to a decrease in the number of medical service providers subscribing to information services on our platform.
Sales of Medical Products and Maintenance Services RMB 76 million, down 28.1% year-over-year, primarily due to a decrease in the order volume of medical products.
Other Services Revenues RMB 23.2 million, down 64% year-over-year, primarily due to a decrease in So-Young Prime.
Cost of Revenues RMB 184.6 million, up 19% year-over-year, primarily due to a business expansion of our branded aesthetic centers.
Cost of Aesthetic Treatment Services RMB 109.4 million, up 405.5% year-over-year, primarily due to the business expansion of our branded aesthetic centers.
Cost of Information and Reservation Services RMB 16.7 million, down 47.4% year-over-year, which was in line with the decrease in revenue generated from information and reservation services.
Cost of Medical Products Sold and Maintenance Services RMB 39.5 million, down 25.8% year-over-year, primarily due to a decrease in costs associated with the sales of medical products.
Cost of Other Services RMB 19 million, down 60.8% year-over-year, primarily due to a decrease in costs associated with So-Young Prime.
Total Operating Expenses RMB 241.3 million, down 1.8% year-over-year.
Sales and Marketing Expenses RMB 131.3 million, down 0.7% year-over-year, primarily due to the decrease of payroll costs.
G&A Expenses RMB 78.8 million, up 11.3% year-over-year, primarily due to an increase in payroll costs associated with the expansion of administrative employees to support our business upgrade and new strategic businesses.
R&D Expenses RMB 31.2 million, down 26.6% year-over-year, primarily attributable to improvements in staff efficiency.
Income Tax Expenses RMB 1.9 million compared with the income tax benefit of RMB 2.6 million in the same period of 2024.
Net Loss Attributable to So-Young International Inc. RMB 36 million compared with net income attributable to So-Young International Inc. of RMB 18.9 million during the same period last year.
Non-GAAP Net Loss Attributable to So-Young International Inc. RMB 30.5 million compared with non-GAAP net income attributable to So-Young International Inc. of RMB 22.2 million during the same period of 2024.
Basic and Diluted Losses per ADS Attributable to Ordinary Shareholders RMB 0.35 and RMB 0.35, respectively, compared with basic and diluted earnings per ADS attributable to ordinary shareholders of RMB 0.18 and RMB 0.18, respectively, during the same period of 2024.
Cash Position RMB 998.6 million as of June 30, 2025, including cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Treatment Offerings: Launched Medical PLLA, Mermaid Skin Booster, and BBL Hero, expanding the medical aesthetics portfolio and increasing ARPU.
Network Expansion: Expanded So-Young Clinic live medical aesthetic chain to 33 centers, with plans to reach 50 centers by year-end, including expansion into second-tier cities.
Customer Base Growth: Active users exceeded 100,000 by June, with over 70% of new customers acquired through low-cost private domain traffic and referrals.
Operational Efficiency: 19 out of 29 centers turned operating cash flow positive, with 13 being profitable on a monthly basis. Gross profit margin for aesthetic treatment services expanded by 5 percentage points sequentially.
Digitalization and AI: Implemented AI-driven solutions for end-to-end management, including self-service booking, check-in, and treatment processes.
Strategic Transition: Aesthetic center business became the largest revenue contributor, marking a critical inflection point in the company's multiyear strategic transition.
Branding and Marketing: Teamed up with international IPs and influencers for campaigns, significantly boosting brand visibility and engagement.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Net Loss: The company reported a net loss of RMB 36 million and a non-GAAP net loss of RMB 30.5 million in Q2 2025, attributed to rapid network expansion and ongoing investments. This financial strain could impact operational sustainability if not managed effectively.
Decline in Revenue Streams: Revenues from information and reservation services decreased by 35.6% year-over-year, and sales of medical products and maintenance services dropped by 28.1%. This decline in key revenue streams could hinder overall financial performance.
High Operating Expenses: Total operating expenses were RMB 241.3 million, with sales and marketing expenses at RMB 131.3 million. While slightly reduced year-over-year, these high costs could pressure profitability.
Customer Acquisition Costs: Although customer acquisition costs remain low, the company is heavily reliant on private domain traffic and referrals, which may not be sustainable long-term if market dynamics shift.
Expansion Risks: The company plans to open 10 new aesthetic centers in Q3 and reach 50 centers by year-end. Rapid expansion could strain resources, dilute operational efficiency, and increase financial risk.
Supply Chain Challenges: A decrease in the order volume of medical products and reliance on certifications for upstream products could pose risks to supply chain stability and cost efficiency.
Market Competition: The company faces competitive pressures in the medical aesthetics industry, which could impact its ability to maintain market share and profitability.
Economic Uncertainty: Broader economic uncertainties could affect consumer spending on non-essential services like medical aesthetics, impacting revenue growth.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Projections for Q3 2025: Aesthetic treatment service revenues are expected to be between RMB 150 million and RMB 170 million, representing a 230.5% to 274.6% increase from the same period in 2024.
Expansion Plans: The company plans to open around 10 new aesthetic centers in Q3 2025, expanding into both first-tier and core second-tier cities. By year-end, the total number of aesthetic centers is expected to reach 50.
Operational Efficiency and Standardization: The company aims to refine its standardized model to enhance operational consistency and efficiency, establishing a robust base for recurring revenues.
Market Leadership and Long-Term Value: Efforts will focus on reinforcing cost advantages, solidifying industry leadership, and creating durable long-term value for shareholders.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the details of the expansion plan for this year and next year, and the strategy for the franchise model?
A:The company plans to grow the number of centers to 50 by the end of this year, with over 10 planned for the second half. In key cities like Beijing, they aim for 10 centers by year-end 2025. Next year's expansion plan will be finalized in Q4, with new openings expected to match or exceed 2025 levels. Long-term, they target 1,000 centers within 8-10 years. Franchising is not an immediate focus due to manageable CapEx and ample cash reserves, but they plan to pilot 2-3 franchise centers in Q4 and determine future franchise expansion based on their performance.
Q:What is the management's view of the growth potential of the Chinese medical aesthetics market and how will they adapt to new competition?
A:Management is optimistic, noting China's medical aesthetic penetration is below 5% compared to over 20% in South Korea, indicating significant growth potential. The light medical aesthetic market in China is expected to reach RMB 340 billion by 2030, with a 30% penetration rate for chains. So-Young aims for a 25% market share, translating to RMB 26 billion. They focus on sustainable low-cost customer acquisition, a diversified supply chain, and operational competence to maintain a competitive edge.
Q:What is the outlook for customer acquisition cost, marketing expenses, and the cost structure?
A:So-Young's average customer acquisition cost is a few hundred RMB, with over 70% of new customers from low-cost private domain traffic and referrals. They plan localized marketing in key cities to enhance brand visibility. They are optimizing cost structure by increasing self-controlled offerings, such as medical lasers and exclusive distribution rights for treatments. Consumable costs are expected to decline as the network scales, enhancing bargaining power in procurement.
Q:Will there be bottlenecks in recruiting doctors and reliance on center managers as the network expands?
A:There are about 40,000 doctors in China's medical aesthetics sector, forming a solid talent pipeline. Newly recruited doctors can quickly gain experience, and So-Young offers benefits like structured training, social insurance, and career paths. Center managers mainly handle on-site management, while other functions are managed by a dedicated operations platform. A digital dashboard monitors operations in real-time, reducing reliance on center managers.
Q:What factors differentiate So-Young's product strategy and planning from others?
A:So-Young focuses on anti-aging treatments, ensuring cost-effectiveness and healthy gross margins for each treatment. They avoid loss-making products and emphasize a curated bestseller model, similar to Sam's Club. They dynamically adjust blockbuster products based on market demand and competitive trends to maintain their leading position.
Q:What are the future development plans for the POP business?
A:The POP business, with high gross and net margins, remains a key profitability pillar. They plan to promote synergies between the POP and aesthetic center business by leveraging traffic from aesthetic centers. A refined merchant classification and rating mechanism will improve traffic monetization efficiency and create incremental growth for the POP business.
Q:Review of Unclear Management Responses
A:None of the questions were avoided or lacked clarity. Management provided detailed and direct responses to all questions.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI solution
ARPU edge
BBL Hero
Beijing Shenzhen
CBDs IP
CEO Chairman
CFO Director
CFO Safe
Chairman Fuk
Chen Haitong
Cheung Citigroup
Haitong International
International Research
Investor
Medical PLLA
Qiao
Research Limited
brand influence
campaign
center customer
center network
density
information reservation
loss
measure
momentum
network expansion
number treatment
point
reputation
reservation service
tier city
training
treatment service
user experience
SY Transcript
So-Young International Inc. (SY) Q1 2026 Earnings Call Transcript
Neutral5-22
So-Young International Inc. (SY) Q4 2025 Earnings Call Transcript
Positive3-25
The earnings call highlights strong financial performance with significant revenue growth, an optimistic guidance, and improved operational metrics. Despite a decrease in cash position due to investments, the overall outlook remains positive with strategic expansion plans and effective cost management. The Q&A section further supports a positive sentiment, with management addressing margin expansion and customer acquisition strategies effectively. The focus on new centers and customer lifetime value enhancement suggests continued growth potential. Thus, the stock price is likely to see a positive movement in the short term.
So-Young International Inc. (SY) Q3 2025 Earnings Call Transcript
Positive11-17
The earnings call reveals a strong revenue projection for Q3 2025, a strategic expansion plan, and operational efficiency improvements. Despite a net loss, the company shows potential with increased core members and repeat customer revenue. The Q&A section confirmed strategic focus on growth and profitability, with a positive reception to new product launches and compliance measures. The strong revenue growth and optimistic guidance, alongside strategic expansion into high-demand areas, suggest a positive sentiment towards future stock performance.
So-Young International Inc. (SY) Q2 2025 Earnings Call Transcript
Positive8-15
The earnings call summary shows strong financial metrics, particularly in revenue growth expectations, and a strategic focus on expansion and vertical integration. While there are net losses, management provides optimistic guidance with plans for significant expansion and market share capture. The Q&A highlights management's confidence in market potential and effective cost strategies, with clear responses to analysts' questions. The partnership with SkinCeuticals and focus on proprietary product development further enhance the positive outlook. Despite the lack of market cap data, the overall sentiment suggests a positive stock price movement.
SY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
